Clinical Nutrition Department, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China.
Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China.
Mol Med Rep. 2020 Sep;22(3):2478-2486. doi: 10.3892/mmr.2020.11302. Epub 2020 Jul 6.
Breast cancer (BC) is the most common malignancy among women worldwide. However, identifying effective biomarkers for the diagnosis and treatment of BC is challenging. Based on our previously developed 'humanized' mouse model of BC, microarray expression analysis was performed and multiple differentially expressed genes, including ribosomal protein (RP) L32, were screened. Recent reports have revealed that RPs are relevant to the development and progression of cancer. However, the expression and function of RPL32 in BC remains unknown. Therefore, in the present study, the role of RPL32 in the development of BC was explored. Immunohistochemical staining and reverse transcription‑quantitative PCR were used, and it was found that RPL32 was upregulated in human BC tissues and cells. Cell Counting Kit‑8, cell invasion and migration assays were performed, which demonstrated that RPL32 knockdown using lentivirus‑delivered small interfering RNA inhibited the migration and invasion of BC cells in vitro and in vivo (nude mouse model). Moreover, western blotting showed that RPL32 knockdown decreased the expression levels of matrix metalloproteinase (MMP)‑2 and MMP‑9. Thus, the present findings indicated a potential oncogenic role of RPL32, suggesting that it may be a novel target for molecular targeted therapy in patients with BC.
乳腺癌(BC)是全球女性中最常见的恶性肿瘤。然而,鉴定用于 BC 的诊断和治疗的有效生物标志物是具有挑战性的。基于我们之前开发的 BC“人源化”小鼠模型,进行了微阵列表达分析,筛选出多个差异表达基因,包括核糖体蛋白(RP)L32。最近的报告表明 RPs 与癌症的发生和进展有关。然而,RPL32 在 BC 中的表达和功能仍然未知。因此,在本研究中,探讨了 RPL32 在 BC 发展中的作用。通过免疫组织化学染色和逆转录-定量 PCR 发现,RPL32 在人 BC 组织和细胞中上调。细胞计数试剂盒-8、细胞侵袭和迁移实验表明,使用慢病毒递送的小干扰 RNA 进行 RPL32 敲低抑制了 BC 细胞在体外和体内(裸鼠模型)的迁移和侵袭。此外,Western blot 显示 RPL32 敲低降低了基质金属蛋白酶(MMP)-2 和 MMP-9 的表达水平。因此,这些发现表明 RPL32 具有潜在的致癌作用,提示其可能成为 BC 患者分子靶向治疗的新靶点。